Tecartus
Payments companies reported to CMS as associated with Tecartus. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tecartus, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tecartus
These are the largest totals companies reported as associated with Tecartus. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Olalekan Oluwole | Nashville, TN | Hematology & Oncology | $16,331.89 |
| Joseph Ibrahim | Bayonne, NJ | $13,800.00 | |
| Muthu Kumaran | Little Rock, AR | Medical Oncology | $13,503.04 |
| Luhua Wang | Houston, TX | Hematology & Oncology | $12,123.72 |
| Nitin Jain | Houston, TX | Internal Medicine | $11,662.94 |
| Ryan Cassaday | Seattle, WA | Hematology & Oncology | $10,230.00 |
| Yucai Wang | Rochester, MN | Hematology & Oncology | $10,154.62 |
| Eunice Wang | Buffalo, NY | Hematology & Oncology | $10,130.17 |
| Jae Park | New York, NY | Hematology & Oncology | $9,570.00 |
| Bijal Shah | Tampa, FL | Hematology & Oncology | $8,040.00 |
Prescribed Tecartus?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.